ADC seems to be more effective than traditional anti-HER2 drugs in HER2-mutated tumors, and objective response rates (ORRs) of 44% and 72.7% have been reported for T-DM1 and T-DXd, respectively, in HER2-mutated NSCLC (3, 9). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.